Biodesix Presents Data Showing Veristrat Useful for Identifying Avastin-Tarceva Responders | GenomeWeb

Biodesix last week presented results from a combined analysis of two Phase II trials using its Veristrat lung cancer companion diagnostic.

The results, which were shared at the Third European Lung Cancer Conference in Geneva, demonstrated that Veristrat was able to identify non-squamous non-small cell lung cancer patients likely to have better and worse survival outcomes when given combination therapy of bevacizumab – marketed by Roche as Avastin – and erlotinib – marketed by Roche as Tarceva.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.

A man is using DNA evidence to argue that he is the rightful heir to the baronetcy of Stichill, the Guardian reports.

As part of an effort to get a diverse group of people to donate their DNA for research, some blood donors in the San Diego area will get their genomes sequenced, according to KPBS.

The comment period on the Department of Health and Human Services' proposal to alter the Common Rule has been extended.